Baseline demographic, disease, and pretreatment characteristics according to induction strategy
| . | Total (N = 100) . | VenAza (n = 44) . | ICH (n = 56) . | P value . |
|---|---|---|---|---|
| Demographics | ||||
| Age, median (range) | 46 (18-78) | 52 (18-78) | 40 (18-73) | .018 |
| Male, n (%) | 46 (46) | 19 (43.2) | 27 (48.2) | .62 |
| ECOG, n (%) | .034 | |||
| 0 | 4 (4) | 4 (9.1) | 0 (0) | |
| 1 | 53 (53) | 25 (56.8) | 28 (50) | |
| 2 | 43 (43) | 15 (34.1) | 28 (50) | |
| Disease characteristics | ||||
| Diagnosis, n (%) | ||||
| De novo∗ | 81 (81) | 27 (61.4) | 54 (96.4) | .0001 |
| MPN∗ | 3 (3) | 3 (6.8) | 0 (0) | |
| MDS∗ | 10 (10) | 9 (20.5) | 1 (1.8) | |
| CMML∗ | 6 (6) | 5 (11.4) | 1 (1.8) | |
| Monocytic features (n = 90), n (%) | 35 (38.9) | 12 (27.9) | 23 (48.9) | .041 |
| ELN 2017 (n = 67), n (%) | .03 | |||
| Non adverse | 47 (70.1) | 17 (56.7) | 30 (81.1) | |
| Adverse∗ | 20 (29.9) | 13 (43.3) | 7 (18.9) | |
| Laboratory values at diagnosis, median (range) | ||||
| Hemoglobin, g/dL | 7 (2.2-13.8) | 7.3 (4.4-11.6) | 6.6 (2.2-13.8) | .155 |
| Leukocytes, 1 × 109/L | 27 (0.6-404) | 8.6 (0.6-372) | 47.1 (0.9-404) | .001 |
| Platelets, 1 × 109/L | 32.7 (2-373) | 34.5 (5-373) | 30.3 (2-196) | 4 |
| Treatment-related variables | ||||
| Cytoreduction, n (%) | 38 (38) | 14 (31.8) | 24 (42.9) | .26 |
| Number of cycles, n (%) | .0001 | |||
| 1 | 75 (75) | 24 (54.5) | 51 (91.1) | |
| 2 | 25 (25) | 20 (45.5) | 5 (8.9) | |
| Days to treatment, median (range) | 5 (0-120) | 7 (0-120) | 4 (0-16) | .006 |
| . | Total (N = 100) . | VenAza (n = 44) . | ICH (n = 56) . | P value . |
|---|---|---|---|---|
| Demographics | ||||
| Age, median (range) | 46 (18-78) | 52 (18-78) | 40 (18-73) | .018 |
| Male, n (%) | 46 (46) | 19 (43.2) | 27 (48.2) | .62 |
| ECOG, n (%) | .034 | |||
| 0 | 4 (4) | 4 (9.1) | 0 (0) | |
| 1 | 53 (53) | 25 (56.8) | 28 (50) | |
| 2 | 43 (43) | 15 (34.1) | 28 (50) | |
| Disease characteristics | ||||
| Diagnosis, n (%) | ||||
| De novo∗ | 81 (81) | 27 (61.4) | 54 (96.4) | .0001 |
| MPN∗ | 3 (3) | 3 (6.8) | 0 (0) | |
| MDS∗ | 10 (10) | 9 (20.5) | 1 (1.8) | |
| CMML∗ | 6 (6) | 5 (11.4) | 1 (1.8) | |
| Monocytic features (n = 90), n (%) | 35 (38.9) | 12 (27.9) | 23 (48.9) | .041 |
| ELN 2017 (n = 67), n (%) | .03 | |||
| Non adverse | 47 (70.1) | 17 (56.7) | 30 (81.1) | |
| Adverse∗ | 20 (29.9) | 13 (43.3) | 7 (18.9) | |
| Laboratory values at diagnosis, median (range) | ||||
| Hemoglobin, g/dL | 7 (2.2-13.8) | 7.3 (4.4-11.6) | 6.6 (2.2-13.8) | .155 |
| Leukocytes, 1 × 109/L | 27 (0.6-404) | 8.6 (0.6-372) | 47.1 (0.9-404) | .001 |
| Platelets, 1 × 109/L | 32.7 (2-373) | 34.5 (5-373) | 30.3 (2-196) | 4 |
| Treatment-related variables | ||||
| Cytoreduction, n (%) | 38 (38) | 14 (31.8) | 24 (42.9) | .26 |
| Number of cycles, n (%) | .0001 | |||
| 1 | 75 (75) | 24 (54.5) | 51 (91.1) | |
| 2 | 25 (25) | 20 (45.5) | 5 (8.9) | |
| Days to treatment, median (range) | 5 (0-120) | 7 (0-120) | 4 (0-16) | .006 |
CMML, chronic myelomonocytic leukemia; ECOG, Eastern Cooperative Group score; MPN, myeloproliferative neoplasm; MDS, myelodysplastic syndrome.
Bonferroni-adjusted post hoc analysis showed significant differences in this subgroup.